Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
PEG-rhG-CSF is a more convenient and safe formulation and a more effective prophylactic measure in breast cancer patients receiving multiple cycles of chemotherapy.
Expression profiles of long noncoding RNAs in lung adenocarcinoma
- B. Zhao, Hang Xu, Shune Yang
- Medicine, BiologyOncoTargets and Therapy
- 1 September 2018
The expression profiles of lncRNAs in lung adenocarcinoma were revealed and LINC00578 was identified as a promising biomarker and therapeutic target for lung adeogenesis and further follow-up study showed that LINC 00578 expression was closely associated with the survival of patients with lungAdenocARCinoma.
MicroRNA-10b regulates epithelial–mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma
- Gulibaha Hujie, Sheng-hua Zhou, Shune Yang
- Biology, MedicineCancer Cell International
- 17 January 2018
The results reveal that miR-10b downregulates KLF4, the inhibitory transcriptional factor of KLF11, which induces Smads signaling activity to promote HCC EMT.
Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma.
- Fangying Chen, Xin-Feng Li, D. Fu, Jian-guo Huang, Shune Yang
- BiologyCancer Biomarkers
The results suggested that miRNA-221 expression level was closely related to tumor stage, number of tumor nodes, and microvascular invasion in HCC patients and could be regarded an important molecular marker for HCC prognosis.
MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1
- Hongge Zhu, Jie Yang, Shune Yang
- Biology, ChemistryExperimental and Therapeutic Medicine
- 3 January 2020
It was demonstrated that miR-103a-3p regulates cisplatin resistance by targeting neurofibromatosis 1 (NF1) via activating ERK signaling in vitro and in vivo, and NF1 was identified as a special miR/3p target in the present study.
Downregulation of MANCR inhibits cancer cell proliferation in mantle cell lymphoma possibly by interacting with RUNX2.
- Shu-juan Wen, Min Zeng, Shune Yang
- BiologyActa Biochimica et Biophysica Sinica
- 18 November 2019
It is concluded that downregulation of MANCR may inhibit cancer cell proliferation in MCL possibly by interacting with RUNX2.
Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure
- Shaoxuan Hu, Yuqin Song, Xiaohui He
- MedicineCancer Science
- 11 November 2018
It is indicated that PB‐DLBCL has a continuous pattern of relapse, especially with frequent late relapses in the CNS and contralateral breast, and neither the addition of rituximab nor prophylactic intrathecal chemotherapy could effectively prevent CNS relapse for PB‐ DLBCL patients.
Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma
- Xin Hu, Min Zeng, Shu-juan Wen
- 1 November 2017
R-CHOP, when compared with CHOP alone, could not improve the RFS and OS of patients with DLBCL and both groups had similar safety profiles.
Profile and outcome of receptor conversion in breast cancer metastases: a nation‐wide multicenter epidemiological study
- Z. Yi, Pei Yu, Bing-he Xu
- Medicine, BiologyInternational Journal of Cancer
- 23 July 2020
The findings showed that the receptors' conversions were common in metastatic breast cancer, and the conversion impacted the survival.
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy
- Shan-shan Chen, Yiqun Han, Bing-he Xu
- Medicine, BiologyBMC Cancer
- 31 March 2021
The prospective randomized controlled trials demonstrated that rHSA/G-CSF was efficacious and well-tolerated with an approachable frequency and expense of application for prophylactic management of agranulocytosis.